Physician profile
James Chappell
NPI 1598726440
$419,713.22
in general payments reported to CMS, 2019-2025
20 companies · $60K in 2025
The $60K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $70K · 2021: $33K · 2022: $46K · 2023: $55K · 2024: $56K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $156K · Travel and Lodging: $10K · Food and Beverage: $4,297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $156,100.00 |
| Travel and Lodging | $10,343.03 |
| Food and Beverage | $4,297.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $402,408.65 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,249.03 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $7,053.99 | 2019-2022 | |
| Novo Nordisk INC | $401.51 | 2022-2024 | |
| Medtronic, INC. | $309.96 | 2021-2023 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Medtronic Minimed, INC. | $214.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $189.68 | 2020-2022 | |
| Amgen INC. | $186.63 | 2021-2025 | Repatha |
| Abbvie INC. | $172.99 | 2020-2024 | |
| Rhythm Pharmaceuticals, INC. | $148.36 | 2024 | Imcivree |
| Chiesi USA, INC. | $112.11 | 2025 | Myalept |
| Sequel Med Tech, LLC | $64.96 | 2025 | Twiist |
| Ibsa Pharma INC. | $49.45 | 2021-2022 | |
| Dexcom, INC. | $35.16 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $32.06 | 2020-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $24.41 | 2021 | |
| Mannkind Corporation | $22.06 | 2023 | Afrezza |
| Amneal Pharmaceuticals LLC | $13.14 | 2024 | Unithroid |
| Sanofi-Aventis U.S. LLC | $12.48 | 2020 | |
| Abbott Laboratories | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Chappell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.